Pedro Hashizume

Medical Oncologist at ICESP/USP and Oncologia D'Or

[Pedro Hashizume @HashizumePedro]

@cmsfrnc Voltou?

[Pedro Hashizume @HashizumePedro]

Check out our paper @LancetRH_Americ
Nice multicenter collaborative effort!

Cholangiocarcinoma in Latin America: a multicentre observational study alerts on ethnic disparities in tumour presentation and outcomes - The Lancet Regional Health – Americas https://t.co/n1aW96AJ6b

[Pedro Hashizume @HashizumePedro]

@cmsfrnc O cancelamento vem

[Pedro Hashizume @HashizumePedro]

@cmsfrnc Hora de abandonar essa rede

[Pedro Hashizume @HashizumePedro]

Result of great teamwork from our friends at @Icesp_ ! Nice job !!

[Cassio Murilo T. Hidalgo Filho @CMHidalgoFilho]

Excited to share our publication in JCO Global Oncology! We analyzed the patterns of unplanned hospitalization among cancer patients in the Brazilian health system. Recognizing these patterns is key to improving cancer care in our country. https://t.co/EZuBtSV5dG

[Pedro Hashizume @HashizumePedro]

Tremendous achievement of @_hanielaraujo and cols in this publication in Cancer Discovery! Congrats my friend!!!

[haniel.araujo @_hanielaraujo]

A mucinous transcriptional program supports long-term tumor cell persistence to RAS inhibitors and mucinous histological features may predict poor resposme to KRAS G12C inhibitors. These important findings provide new insights for drug development targeting KRAS-mutant NSCLC.

[Pedro Hashizume @HashizumePedro]

@dr_yakupergun @OncoAlert @Annals_Oncology Dr, despite numerical difference and myself belief in TNT benefit, what about statistical plan modification from original? I mean, analysis from the original plan, turns the results negative.

[Pedro Hashizume @HashizumePedro]

The standards for approvals should be higher
Surrogate endpoints must be well validated to become useful
Unfortunately, physician's choice isnt the best choice. Then regulatory agencies may balance that.

[Deniz Can Guven @DenizCanGuven1]

Out in @TheLancetOncol in OA

The OS benefits of cancer drugs approved by surrogate endpoints

☑️38 indications with OS data after approval
❎Significant OS benefit in only 32% of the indications
❎Late availability of (>3 years) non-significant OS results

The value of surrogate endpoints in approvals ❓❓
A double-edged sword ⚔️

#OncoAlertAF #CSO @OncoAlert
@VPrasadMDMPH @oncology_bg @darioT_ @cspramesh
@ASCO @myESMO @ESOncology @LSEnews

[Pedro Hashizume @HashizumePedro]

@SuyogCancer @rushabh1388 @myESMO Dr, do you think Pembro for 2 years should be broadly used in LACC? A subgroup would be cured with just CRT, and benefit is still PFS only (besides subsequent treatemens discussion...)

[Pedro Hashizume @HashizumePedro]

@cmsfrnc Que isso mano mano

[Pedro Hashizume @HashizumePedro]

@AndradeMO_MD @UChicago @RitaNandaMD @MsNanchen Congratulations!! Much more to accomplish ahead!

[Pedro Hashizume @HashizumePedro]

@cmsfrnc Que isso

[Pedro Hashizume @HashizumePedro]

@paulosiqamaral What is FICO score?

[Felippe Lazar @felippelazar]

Our work in global representativeness, pharm. funding and cost-effectiveness research have recently been published at The Breast (https://t.co/IdI8LCH0oT).

Although our findings are not necessarily new, diving deep in this topic is worthy of some important considerations.

/n

[Pedro Hashizume @HashizumePedro]

@cmsfrnc À esquerda dos radiologistas ou à esquerda comum?

[Fred Fernandes @FredLAFernandes]

Corredores 🏃🏻 do Twitter! Olha um evento legal do hospital que eu trabalho. Corrida ICESPRUN

🗓️ 3/12
🕖 7h
📍 Praça Charles Miller

5k e 10k corrida. 5k caminhada. Bateria kids > 4 anos.
O dinheiro do evento auxilia projetos do ICESP

Inscrições no site: https://t.co/x9BA72da7Z

[Pedro Hashizume @HashizumePedro]

@cmsfrnc @PepitoTheCat YEAHHHHHHH

[Pedro Hashizume @HashizumePedro]

@cmsfrnc @PepitoTheCat PEPITOOOO

[Pedro Hashizume @HashizumePedro]

@cmsfrnc 🥰

[Pedro Hashizume @HashizumePedro]

@cmsfrnc 😘 i ll be back